5 recruiting, 1 active not recruiting, 1 terminated. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 3 |
| Phase 2 | 3 | Active not recruiting 1, Recruiting 1, Terminated 1 |
Follow Ciltacabtagene Autoleucel: new trials by email Literature Review of Ciltacabtagene Autoleucel trials Research Report on Ciltacabtagene Autoleucel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma Lymphodepleting chemotherapy: Cyclophosphamide, Lymphodepleting chemotherapy: Bendamustine, Lymphodepleting chemotherapy: Fludarabine - Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM) | Phase 1 | Recruiting | Weill Medical College of Cornell University | 32 | 2026-11-01 | 2026-10-26 |
| Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma Talquetamab, Ciltacabtagene Autoleucel - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | Medical College of Wisconsin | 31 | 2025-12-02 | 2026-01-05 |
| Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | Mayo Clinic | 44 | 2025-09-18 | 2026-08-26 |
| The Norwegian Immunotherapy in Multiple Myeloma Study Teclistamab, Elranatamab, Ciltacabtagene Autoleucel - Myeloma Multiple, Plasma Cell Leukemia | Recruiting | St. Olavs Hospital | 400 | 2025-01-15 | 2026-07-20 | |
| Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function Cyclophosphamide, Ciltacabtagene Autoleucel, Total body irradiation - Multiple Myeloma | Phase 1 | Recruiting | Washington University School of Medicine | 16 | 2024-12-04 | 2026-03-11 |
| CAR- PRISM (PRecision Intervention Smoldering Myeloma) Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine Phosphate - Multiple Myeloma, Smoldering Multiple Myeloma | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 20 | 2023-04-19 | 2026-03-12 |
| A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma LCAR-B38M CAR-T Cell - Multiple Myeloma | Phase 2 | Terminated | Nanjing Legend Biotech Co. | 123 | 2019-01-23 | 2025-12-17 |
Multiple Myeloma (7) · Immunoglobulin Light-chain Amyloidosis (1) · Infections (1) · Leukemia, Plasma Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Recurrence (1) · Renal Insufficiency (1) · Smoldering Multiple Myeloma (1)
Dana-Farber Cancer Institute (1) · Mayo Clinic (1) · Medical College of Wisconsin (1) · Nanjing Legend Biotech Co. (1) · St. Olavs Hospital (1) · Washington University School of Medicine (1) · Weill Medical College of Cornell University (1)
United States (5) · China (1) · Norway (1)
Caitlin Gribbin, MD (1) · Irene Ghobrial, MD (1) · Michael J Slade, M.D., MSCI (1) · Othman Akhtar, MBBS (1) · Yi Lin, MD, PhD (1)
P50CA186781 (1)